Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Biocytogen and Sihuan Pharma Forge Strategic Partnership to Accelerate Innovative Drug Development Including Weight Management Therapies

Fineline Cube Apr 2, 2026
Company Deals

Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal

Fineline Cube Apr 2, 2026
Company Deals Drug

Zai Lab and Amgen Partner to Evaluate ADC-BiTE Combination Therapy for Extensive-Stage Small Cell Lung Cancer

Fineline Cube Apr 2, 2026
Company Deals

Shanghai BDgene Secures Hundreds of Millions in Financing to Advance Dual Gene Therapy Platforms

Fineline Cube Apr 2, 2026
Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Fineline Cube Apr 1, 2026
Policy / Regulatory

China’s CDE Releases 105th Batch of Reference Preparations for Generic Drug Evaluation, Adds 8 New Drugs

Fineline Cube Apr 2, 2026
Company Drug

RemeGen Secures NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors

Fineline Cube Apr 2, 2026
Company Drug

Fosun Pharma Secures NMPA Approval for Phase I Trial of HLX319, Biosimilar to Roche’s Phesgo for HER2-Positive Breast Cancer

Fineline Cube Apr 2, 2026
Company Deals

EC Healthcare Partners with Jiangxi Rimag Group to Expand Medical Imaging Services

Fineline Cube Nov 22, 2023

China-based EC Healthcare (HKG: 2138) has entered into a partnership with Jiangxi Rimag Group Co.,...

Company Deals

Dizal Pharmaceutical and Wuxi Gaofa Investment to Establish Joint Venture for Auto-Immune Disease Treatments

Fineline Cube Nov 22, 2023

China-based AstraZeneca (AZ, NASDAQ: AZN) spin-out, Dizal Pharmaceutical Co., Ltd (SHA: 688192), has entered into...

Company Deals

BeiGene Ltd Strikes Exclusive Global License Deal with Ensem Therapeutics for CDK2 Inhibitor

Fineline Cube Nov 22, 2023

China-based biopharmaceutical company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced a licensing...

Company Drug

Fosun Pharmaceutical’s FCN-437c filing Accepted for Review by China’s NMPA

Fineline Cube Nov 22, 2023

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has announced that the National...

Company Deals

XtalPi Inc. and Singapore’s EDDC Broaden Collaboration in AI-Driven Drug Discovery

Fineline Cube Nov 22, 2023

Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has entered into a memorandum of...

Company

Merck KGaA Completes Second Phase of Biologics Testing Center Expansion in China

Fineline Cube Nov 22, 2023

Germany’s major life science company, Merck KGaA (ETR: MRK), has announced the completion of the...

Company

Belgium Bans Ozempic for Weight Loss as Global Shortage Persists

Fineline Cube Nov 21, 2023

Belgium has issued a royal decree prohibiting the use of Novo Nordisk’s (NYSE: NVO) diabetes...

Company Deals

Asia Regenerative Medicine Secures Pre-Series A Financing for Bioartificial Organ Development

Fineline Cube Nov 21, 2023

Shenzhen-based bioartificial organ developer, Asia Regenerative Medicine, has reportedly raised tens of millions of renminbi...

Company Drug

CSPC Pharmaceutical’s Glumetinib Earns Breakthrough Therapy Designation in China

Fineline Cube Nov 21, 2023

Glumetinib, a MET targeted tyrosine kinase inhibitor (TKI) co-developed by CSPC Pharmaceutical Group Ltd (HKG:...

Company Medical Device

AstraZeneca Launches Evinova to Enhance Global Clinical Development with Digital Health Solutions

Fineline Cube Nov 21, 2023

UK-based AstraZeneca (AZ; NASDAQ: AZN) has launched Evinova, a digital health solutions provider, with the...

Company Drug

BMS and 2seventy Bio’s Abecma Faces FDA Review Extension

Fineline Cube Nov 21, 2023

The US Food and Drug Administration (FDA) has postponed the target action date for Bristol...

Company Deals

Suzhou Porton Biologics Partners with Asclepius Technology for NK Cell Project

Fineline Cube Nov 21, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...

Company

Shanghai Pharmaceuticals’ Chairman Zhou Jun Resigns Amid Investigation

Fineline Cube Nov 21, 2023

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading Chinese pharmaceutical distribution company, has announced...

Company Deals

VIVA Biotech Holdings Secures Nearly USD 210 Million in Financing Round

Fineline Cube Nov 21, 2023

China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has announced the completion of...

Company Drug

Jiangsu Aidea Pharmaceutical’s AINUOVIRINE Receives Priority Review Status from CDE

Fineline Cube Nov 21, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a Chinese pharmaceutical company, has announced that its...

Company Drug

Medilink Therapeutics’ YL201 Earns Orphan Drug Designation for Esophageal Cancer

Fineline Cube Nov 21, 2023

Suzhou-based Medilink Therapeutics has announced that it has obtained orphan drug designation (ODD) from the...

Company Deals

Chiesi Farmaceutici Acquires Global Rights to Haisco Pharmaceutical’s HSK31858 for Respiratory Diseases

Fineline Cube Nov 21, 2023

Italy-based Chiesi Farmaceutici S.p.A has announced a licensing agreement with China-based Haisco Pharmaceutical Group Co.,...

Company Deals

Fosun Pharmaceutical’s US Subsidiary Partners with Treehill Partners for Clinical-Stage Investments

Fineline Cube Nov 21, 2023

Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) through its US subsidiary, Fosun Pharma...

Company Deals

Jiangsu Aidea Pharmaceutical Partners with Fidson Healthcare for HIV/AIDS Treatments in Nigeria

Fineline Cube Nov 20, 2023

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has reportedly entered into a strategic cooperation...

Company Deals

GE Healthcare’s Shanghai Innovation Hub Onboards Initial Start-Ups

Fineline Cube Nov 20, 2023

GE Healthcare’s (NASDAQ: GEHC) newly established Shanghai innovation center, dedicated to advancing healthcare projects, has...

Posts pagination

1 … 420 421 422 … 645

Recent updates

  • RemeGen Secures NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors
  • Biocytogen and Sihuan Pharma Forge Strategic Partnership to Accelerate Innovative Drug Development Including Weight Management Therapies
  • Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal
  • Fosun Pharma Secures NMPA Approval for Phase I Trial of HLX319, Biosimilar to Roche’s Phesgo for HER2-Positive Breast Cancer
  • NMPA Approves World’s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

RemeGen Secures NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors

Company Deals

Biocytogen and Sihuan Pharma Forge Strategic Partnership to Accelerate Innovative Drug Development Including Weight Management Therapies

Company Deals

Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal

Company Drug

Fosun Pharma Secures NMPA Approval for Phase I Trial of HLX319, Biosimilar to Roche’s Phesgo for HER2-Positive Breast Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.